Anti-pneumococcal polysaccharide antibody (Anti-PnPS)

Anti-pneumococcal polysaccharide antibodies are specialized immunoglobulins, primarily of the IgG class, that are generated by the adaptive immune system following exposure to pneumococcal capsular polysaccharides through vaccination or infection (CDC, 2022). These antibodies are directed against the complex carbohydrate structures that form the outer capsule of Streptococcus pneumoniae, which is the bacterium's primary defense against the host immune system. By binding to these polysaccharides, the antibodies neutralize the anti-phagocytic properties of the capsule and facilitate opsonophagocytosis, a process where the bacteria are marked for destruction by neutrophils and macrophages (Pollard et al., 2009). This immune response is the primary mechanism by which vaccines like the pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) and the pneumococcal polysaccharide vaccine (PPSV23) provide protection against invasive diseases such as pneumonia, meningitis, and febrile bacteremia (FDA, 2021). In clinical research and vaccine development, the concentration and functional activity of these antibodies, measured via ELISA and opsonophagocytic activity (OPA) assays, serve as essential correlates of protection and primary endpoints for evaluating vaccine efficacy (WHO, 2019). However, because these antibodies are highly serotype-specific, they do not offer protection against pneumococcal strains whose polysaccharides are not included in the vaccine formulation, a factor that contributes to the phenomenon of serotype replacement in vaccinated populations.

Other names

Pneumococcal capsular polysaccharide antibodiesAnti-PnPS IgGPneumococcal antibodiesSerotype-specific pneumococcal antibodies

Vaccines containing pneumococcal polysaccharides (conjugated or unconjugated) stimulate B-lymphocytes to differentiate into plasma cells that secrete serotype-specific antibodies. These antibodies bind to the bacterial capsule, facilitating opsonophagocytosis and complement-mediated lysis of Streptococcus pneumoniae (Pollard et al., 2009; WHO, 2019).